logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy sews up £24mln financing deal to bring cancer breakthrough to London

The AIM-listed firm is using technology developed by scientists working on the large hadron collider at the CERN facility in Switzerland to create a low-cost proton beam treatment for cancer.

picture of scientists in the control centre for the large hadron collider.
Scientists working trying to identify the 'God particle' have also helped in the battle against cancer.

Advanced Oncotherapy PLC (LON:AVO) has signed a deal that will allow it provide up to £24mln of vendor financing for the company’s first LIGHT machine in Harley Street, London.

Last October the company announced the formation of the proton beam cancer therapy centre in the capital.

The London Proton Therapy Centre will be funded with £6mln of equity from Advanced Oncotherapy and its partners along with a vendor loan from AVO.

A fund advised by Metric Capital is providing the cash. Shortly following the signing of the deal, £11mln can be drawn down.

The remainder becomes available following the completion of a £25mln cash or capital injection to bankroll the development of a manufacturing base.

AIM-listed AVO is using technology developed by scientists working on the large hadron collider at the CERN facility in Switzerland to create a low-cost proton beam treatment for cancer.

The technology is called LIGHT, which stands for Linac Image Guided Hadron Technology.

Read - What is proton beam therapy?

Cheaper and smaller than the current units, which are almost prohibitively expensive, the LIGHT system has the ability to propel protons at the speeds generated by much larger machines.

Proton beam therapy is expected to emerge as the go-to treatment for tumours as the price of the technology comes down.

It uses the aforementioned protons to pinpoint tumours more precisely.

This limits the damage caused by radiation to surrounding tissue and organs as well as offering patients higher disease-free survival rates.

The piece of the kit that accelerates the protons was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the "God particle".

Chief operating officer Nicolas Serandour said vendor financing of the sort announced today had become an integral component to developing undertakings of this kind.

"We are delighted to have secured this financing partnership with Metric Capital,” he added.

The company’s partners include international companies such as Thales, Toshiba and VDL.

Quick facts: Advanced Oncotherapy PLC

Price: 27.25 GBX

LSE:AVO
Market: LSE
Market Cap: £83.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Advanced Oncotherapy One2One Investor Presentation 29th October 2013-DUBLIN

Advanced Oncotherapy One2One Investor Presentation 29th October 2013-DUBLIN

on 10/29/2013

2 min read